RA PHARMACEUTICALS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
RA PHARMACEUTICALS, INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$102.69 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2020-02-27
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-12-31 was -$36.78M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was -$24.98M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was -$21.90M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was -$19.04M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$102.69M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$64.94M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$54.44M.
- RA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2016 was -$28.86M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$36.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$61.75M derived: sum of 2 quarters · filed 2020-02-27 | -$83.65M derived: sum of 3 quarters · filed 2020-02-27 | -$102.69M 10-K · filed 2020-02-27 |
| 2019-09-30 | -$24.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$46.87M derived: sum of 2 quarters · filed 2019-11-07 | -$65.91M 10-Q · filed 2019-11-07 | -$82.11M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | -$21.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$40.94M 10-Q · filed 2019-08-07 | -$57.13M derived: sum of 3 quarters · filed 2020-02-27 | -$73.64M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | -$19.04M 10-Q · filed 2019-05-09 | -$35.23M derived: sum of 2 quarters · filed 2020-02-27 | -$51.74M derived: sum of 3 quarters · filed 2020-02-27 | -$67.48M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | -$16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$32.70M derived: sum of 2 quarters · filed 2020-02-27 | -$48.45M derived: sum of 3 quarters · filed 2020-02-27 | -$64.94M 10-K · filed 2020-02-27 |
| 2018-09-30 | -$16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$32.25M derived: sum of 2 quarters · filed 2019-11-07 | -$48.75M 10-Q · filed 2019-11-07 | -$63.89M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$15.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$32.24M 10-Q · filed 2019-08-07 | -$47.38M derived: sum of 3 quarters · filed 2019-08-07 | -$62.66M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$16.50M 10-Q · filed 2019-05-09 | -$31.64M derived: sum of 2 quarters · filed 2019-05-09 | -$46.91M derived: sum of 3 quarters · filed 2019-05-09 | -$59.58M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | -$15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$30.42M derived: sum of 2 quarters · filed 2019-03-07 | -$43.08M derived: sum of 3 quarters · filed 2019-03-07 | -$54.44M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$15.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$27.94M derived: sum of 2 quarters · filed 2018-11-07 | -$39.30M 10-Q · filed 2018-11-07 | -$50.19M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | -$12.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$24.02M 10-Q · filed 2018-08-08 | -$34.91M derived: sum of 3 quarters · filed 2018-08-08 | -$43.02M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | -$11.36M 10-Q · filed 2018-05-09 | -$22.25M derived: sum of 2 quarters · filed 2018-05-09 | -$30.36M derived: sum of 3 quarters · filed 2018-05-09 | |
| 2016-12-31 | -$10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$19.00M derived: sum of 2 quarters · filed 2018-03-14 | -$28.86M 10-K · filed 2018-03-14 | |
| 2016-09-30 | -$8.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$17.98M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | -$9.86M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$13.94M 10-K · filed 2018-03-14 |